Latest Breaking News On - Activity impairment questionnaire - Page 6 : comparemela.com

Lancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia

/PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive data from the Phase 3 multicenter, placebo-controlled, double-blind,.

Jazz Pharmaceuticals plc: Lancet Neurology Publishes Positive, Pivotal Phase 3 Data of Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia

Treatment with Xywav resulted in clinically meaningful improvement in idiopathic hypersomnia symptoms, including excessive daytime sleepiness, sleep inertia and prolonged sleep duration with

Employees Lose More When Workplace Programs Include Antiobesity Medications

Chiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly

Message : Required fields NEEDHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patients with acromegaly reported significantly improved quality of life and work productivity after transitioning from long-acting injectable somatostatin analogs (iSSAs) to MYCAPSSA ®. The data were shared as an oral presentation at the 30 th Annual American Association of Clinical Endocrinology (AACE) Meeting being held virtually from May 26-29, 2021. “The encouraging PROs data from the MPOWERED study further our understanding of the potential positive clinical impact that MYCAPSSA has for patients with acromegaly,” said Nienke Biermasz, M.D., Ph.D., Presenting Author. “These PROs provide important information to help physicians assess disease and treatment burden for patients treated with iSSAs and may provide the c